🔗 Permalink

Inventor profile of:

Eric Konofal

City:

Senlis

Country:

France

Published Applications:

19

Last publication date:

2025-08-28

Top Assignees for applications by Eric Konofal

The entities that hold a legal rights for patent applications filed by inventor Konofal Eric:

Assistance Publique-Hopitaux De Paris 6 Paris, France
NLS Pharmaceutics AG 4 Zurich, Switzerland
NLS Pharma AG 1 Stans, Switzerland
NLS Pharmaceutics AG 1 Stans, Switzerland

Recent patent applications by Konofal Eric

Eric Konofal from Senlis, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-28

US20250268859A1

Human necessities

OXAFURAMINE, (1R)-N-ETHYL-1-[(2R)-OXOLAN-2-YL]-2-PHENYLETHANAMINE, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR TREATING ALZHEIMER'S DISEASE (AD), VASCULAR DEMENTIA, DEMENTIA WITH LEWY BODIES (DLB), MIXED DEMENTIA, FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AND PARKINSON'S DISEASE (PD)

#2 | 2025-03-13

US20250082598A1

Human necessities

Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease

#3 | 2025-02-13

US20250049737A1

Human necessities

Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

#4 | 2024-09-26

US20240316023A1

Human necessities

BENEDIN, PIPERIDINE, 2-BENZHYDRYL-3-HYDROXY-N-METHYL-, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR USE IN TREATING KLEINE-LEVIN SYNDROME

#5 | 2024-04-04

US20240108605A1

Human necessities

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY

#6 | 2022-02-24

US20220054471A1

Human necessities

PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

#7 | 2021-04-01

US20210093614A1

Human necessities

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY

#8 | 2020-02-27

US20200061044A1

Human necessities

PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

#9 | 2019-10-31

US20190328714A1

Human necessities

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY

#10 | 2018-08-02

US20180214436A1

Human necessities

Phacetoperane for treating of attention deficit hyperactivity disorder

#11 | 2017-09-07

US20170252325A1

Human necessities

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY

#12 | 2017-06-01

US20170151197A1

Human necessities

LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF

#13 | 2016-02-04

US20160030394A1

Human necessities

Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity

#14 | 2015-02-05

US20150038533A1

Human necessities

PHACETOPERANE FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

#15 | 2013-11-07

US20130295196A1

Chemistry; metallurgy

Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof

#16 | 2012-12-06

US20120308668A1

Human necessities

MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY

#17 | 2011-09-15

US20110223260A2

Human necessities

Mazindol combination in the treatment of attention deficit/hyperactivity

#18 | 2011-07-28

US20110183009A1

Human necessities

Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity

#19 | 2009-05-28

US20090136593A1

Human necessities

Mazindol combination in the treatment of attention deficit/hyperactivity

InventorID:

518178 ⎘